JOP20220339A1 - Methods and compositions for treating chemotherapy-induced diarrhea - Google Patents

Methods and compositions for treating chemotherapy-induced diarrhea

Info

Publication number
JOP20220339A1
JOP20220339A1 JOP/2022/0339A JOP20220339A JOP20220339A1 JO P20220339 A1 JOP20220339 A1 JO P20220339A1 JO P20220339 A JOP20220339 A JO P20220339A JO P20220339 A1 JOP20220339 A1 JO P20220339A1
Authority
JO
Jordan
Prior art keywords
diarrhea
methods
compositions
induced diarrhea
treating chemotherapy
Prior art date
Application number
JOP/2022/0339A
Other languages
Arabic (ar)
Original Assignee
Napo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Napo Pharmaceuticals Inc filed Critical Napo Pharmaceuticals Inc
Publication of JOP20220339A1 publication Critical patent/JOP20220339A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
JOP/2022/0339A 2020-06-19 2020-06-19 Methods and compositions for treating chemotherapy-induced diarrhea JOP20220339A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/038691 WO2021257089A1 (en) 2020-06-19 2020-06-19 Methods and compositions for treating chemotherapy-induced diarrhea

Publications (1)

Publication Number Publication Date
JOP20220339A1 true JOP20220339A1 (en) 2023-01-30

Family

ID=79268234

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0339A JOP20220339A1 (en) 2020-06-19 2020-06-19 Methods and compositions for treating chemotherapy-induced diarrhea

Country Status (10)

Country Link
EP (1) EP4168027A4 (en)
JP (1) JP2023538186A (en)
KR (1) KR20230027226A (en)
AU (1) AU2020454132A1 (en)
BR (1) BR112022025741A2 (en)
CA (1) CA3182864A1 (en)
IL (1) IL299028A (en)
JO (1) JOP20220339A1 (en)
MX (1) MX2022016367A (en)
WO (1) WO2021257089A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115089592B (en) * 2022-05-21 2024-02-27 复旦大学 Application of multiple tyrosine kinase in preparation of medicines for inhibiting enterovirus 71 type neurotropic viruses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011044167A1 (en) * 2009-10-06 2011-04-14 University Of California, San Francisco Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
PT2632550T (en) * 2010-10-31 2017-08-02 Napo Pharmaceuticals Inc Methods and compositions for treating hiv-associated diarrhea
US20160067311A1 (en) * 2014-09-10 2016-03-10 Helsinn Healthcare Sa Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
JP2018509382A (en) * 2015-01-09 2018-04-05 ジャガー ヘルス， インク．Ｊａｇｕａｒ Ｈｅａｌｔｈ， Ｉｎｃ． How to treat diarrhea in companion animals
US20190290675A1 (en) * 2016-12-06 2019-09-26 Kaleido Biosciences, Inc. Glycan polymers and related methods thereof

Also Published As

Publication number Publication date
CA3182864A1 (en) 2021-12-23
EP4168027A1 (en) 2023-04-26
KR20230027226A (en) 2023-02-27
BR112022025741A2 (en) 2023-01-03
MX2022016367A (en) 2023-01-30
JP2023538186A (en) 2023-09-07
EP4168027A4 (en) 2024-04-03
IL299028A (en) 2023-02-01
WO2021257089A1 (en) 2021-12-23
AU2020454132A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
MX2013004873A (en) Methods and compositions for treating hiv-associated diarrhea.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
MX2020009773A (en) Combination therapy.
WO2007130882A3 (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
MX2023000735A (en) Kat6 inhibitor methods and combinations for cancer treatment.
MX2020001768A (en) Methods of treatment of osteoarthritis with transdermal cannabidiol gel.
MX2023004156A (en) Combination therapy for treating cancer.
CR20210514A (en) Use of reboxetine to treat narcolepsy
MX2023013403A (en) Pharmaceutical composition for preventing or treating fibrosis.
DK1677806T3 (en) Compositions for the treatment of acute and congestion-induced sprains and stretching using hyaluronic acid
JOP20220339A1 (en) Methods and compositions for treating chemotherapy-induced diarrhea
JOP20190276A1 (en) Methods and compositions for treating bile acid diarrhea, diarrhea associated with small intestine resection or gallbladder removal, and short bowel syndrome
MX2020008881A (en) Methods of treatment of cancer comprising chk1 inhibitors.
MX2023015097A (en) Treatment of symptoms associated with myeloproliferative neoplasms.
MX2021009488A (en) Use of vibegron to treat overactive bladder.
MX2022011725A (en) Methods of treating pulmonary injury with cgrp inhibitors.
MX2023006704A (en) Dsg2 compositions and methods for the treatment of covid-19.
MX2022004785A (en) Methods and compositions for treatment of rett syndrome.
MY200960A (en) Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury
CL2022003634A1 (en) Methods and compositions for the treatment of diarrhea induced by chemotherapy.
MX2022012234A (en) Caspase inhibitors to enhance injury repair and to treat bacterial and viral infections.
EA202000298A1 (en) ANTICORONAVIRUS AGENT FOR COMBINATION THERAPY OF COVID-19 (SARS-CoV-2) AND METHOD OF TREATMENT
WO2021038500A3 (en) Esketamine for the treatment of patients with major depressive disorder, including suicidality
MY174065A (en) Methods and compositions for treating hiv-associated diarrhea
WO2020061067A3 (en) Compositions and methods for treating bone injury